The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids.
The kallikrein family is a group of 15 serine protease genes clustered on chromosome 19q13.4. Binding of kallikreins to protease inhibitors is an important mechanism for regulating their enzymatic activity and may have potential clinical applications. Human kallikrein gene 5 (KLK5) is a member of this family and encodes for a secreted serine protease (hK5). This kallikrein was shown to be differentially expressed at the mRNA and protein levels in diverse malignancies. Our objective was to study the enzymatic activity and the interaction of recombinant hK5 protein with protease inhibitors. Recombinant hK5 protein was produced in yeast and mammalian expression systems and purified by chromatography. HPLC fractionation, followed by ELISA-type assays, immunoblotting and radiolabeling experiments were performed to detect the possible interactions between hK5 and proteinase inhibitors in serum. Enzymatic deglycosylation was performed to examine the glycosylation pattern of the protein. The enzymatic activity of hK5 was tested using trypsin and chymotrypsin-specific synthetic fluorogenic substrates. In serum and ascites fluid, in addition to the free ( approximately 40 kDa) form, hK5 forms complexes with alpha(1)-antitrypsin and alpha(2)-macroglobulin. These complexes were detected by hybrid ELISA-type assays using hK5-specific coating antibodies and inhibitor detection antibodies. The ability of hK5 to bind to these inhibitors was further verified in vitro. Spiking of serum samples with 125I-labeled hK5 results in the distribution of the protein in two higher molecular mass (bound) forms, in addition to the unbound form. The hK5 mature enzyme is active and shows trypsin, but not chymotrypsin-like, activity. The pro-form of hK5 is not active. Recombinant hK5 shows a higher than predicted molecular mass due to glycosylation. hK5 is partially complexed with alpha(1)-antitrypsin and alpha(2)-macroglobulin in serum and ascites fluid of ovarian cancer patients. The recombinant protein is glycosylated and its mature form shows trypsin-like activity.
Yousef
George M
GM
Department of Pathology and Laboratory Medicine, Division of Clinical Biochemistry, Mount Sinai Hospital, 600 University Avenue, M5G 1X5, Toronto, ON, Canada.
Kapadia
Carl
C
Polymeris
Mary-Ellen
ME
Borgono
Carla
C
Hutchinson
Shirley
S
Wasney
Gregory A
GA
Soosaipillai
Antoninus
A
Diamandis
Eleftherios P
EP
D000818:Animals; D001202:Ascitic Fluid / Q000737:chemistry / Q000378:metabolism*; D016466:CHO Cells / Q000378:metabolism; D005591:Chemical Fractionation; D002850:Chromatography, Gel; D006224:Cricetinae; D005260:Female; D005822:Genetic Vectors; D006031:Glycosylation; D006801:Humans; D007610:Kallikreins / Q000097:blood / Q000737:chemistry / Q000378:metabolism*; D008895:Milk, Human / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000097:blood / Q000737:chemistry / Q000378:metabolism*; D011994:Recombinant Proteins / Q000378:metabolism; D015842:Serine Proteinase Inhibitors / Q000737:chemistry*; D044967:Serum / Q000737:chemistry; D013379:Substrate Specificity
D011994:Recombinant Proteins; D015842:Serine Proteinase Inhibitors; C400147:KLK5 protein, human; D007610:Kallikreins